We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score–matched case-control analysis.
- Authors
Karkouti, Keyvan; Beattie, W. Scott; Wijeysundera, D.N.; Yau, Terrence M.; McCluskey, Stuart A.; Ghannam, Mohammed; Sutton, David; van Rensburg, Adriaan; Karski, Jacek
- Abstract
Cardiac surgery is occasionally complicated by massive blood loss that is refractory to standard hemostatic interventions. Recombinant factor VIIa (rF-VIIa) is being increasingly used as rescue therapy in such cases, but little information is available on its safety and efficacy for this indication.The outcomes of the first 51 cardiac surgery patients who received rF-VIIa for intractable blood loss (from November 2002 to February 2004) at a single institution according to a standardized clinical guideline were compared to 51 matched control patients, with the control patients identified from a large database and matched based on the propensity for massive blood loss.Blood loss and blood product usage were significantly decreased after 2.4 to 4.8 mg of rF-VIIa. In those treated after sternal closure (n = 32), there was a significant reduction in blood loss from the hour before to the hour after treatment: 100 (70, 285) mL (median[25th, 75th percentiles]; p < 0.0001). Except for a slower postoperative recovery and higher incidence of acute renal dysfunction, the adverse event rates were similar between the rF-VIIa-treated patients and their matched controls.These results suggest that rF-VIIa may be an effective rescue therapy for patients with intractable hemorrhage after cardiac surgery. A clinically important risk of stroke or other major thrombotic complications could not be ruled out by our study. Controlled clinical trials with adequate power to detect the impact of rF-VIIa therapy on morbidity and mortality therefore are necessary before one can recommend its routine use in patients undergoing cardiac surgery who have excessive bleeding.
- Subjects
CARDIAC surgery; PATIENTS; PREOPERATIVE care; HEMORRHAGE; CLINICAL trials; THERAPEUTICS
- Publication
Transfusion, 2005, Vol 45, Issue 1, p26
- ISSN
0041-1132
- Publication type
Article
- DOI
10.1111/j.1537-2995.2005.04216.x